Patienterne blev randomiseret til enten at forsætte deres hidtidige behandling ved studiestart eller til at skifte til MIRCERA for at opnå stabile hæmoglobinkoncentrationer.
Patients were randomized to stay on their treatment at the time of enrollment or to be switched to MIRCERA in order to maintain stable haemoglobin levels.